MCR-1

Last updated
Probable phosphatidylethanolamine transferase Mcr-1
Identifiers
Organism Escherichia coli
Symbolmcr1
UniProt A0A0R6L508
Search for
Structures Swiss-model
Domains InterPro
E. coli, the bacterium in which MCR-1 was first identified. E. coli Bacteria (7316101966).jpg
E. coli , the bacterium in which MCR-1 was first identified.

The mobilized colistin resistance (mcr) gene confers plasmid-mediated resistance to colistin, one of a number of last-resort antibiotics for treating Gram-negative infections. mcr-1, the original variant, is capable of horizontal transfer between different strains of a bacterial species. After discovery in November 2015 in E. coli (strain SHP45) from a pig in China it has been found in Escherichia coli , Salmonella enterica , Klebsiella pneumoniae , Enterobacter aerogenes , and Enterobacter cloacae . As of 2017, it has been detected in more than 30 countries on 5 continents in less than a year.

Contents

Description

The "mobilized colistin resistance" (mcr-1) gene confers plasmid-mediated resistance to colistin, a polymyxin and one of a number of last-resort antibiotics for treating infections. [1] [2] The gene is found in no less than ten species of the Enterobacteriaceae: Escherichia coli , Salmonella , Klebsiella pneumoniae , Enterobacter aerogenes , Enterobacter cloacae , Cronobacter sakazakii , Shigella sonnei , Kluyvera species, Citrobacter species, and Raoultella ornithinolytica .[ citation needed ]

The mechanism of resistance of the MCR gene is a lipid A phosphoethanolamine transferase. The enzyme transfers a phosphoethanolamine residue to the lipid A present in the cell membrane of gram-negative bacteria. The altered lipid A has much lower affinity for colistin and related polymyxins resulting in reduced activity of the antimicrobial. This type of resistance is known as target modification. [3] Although the same mechanism has been observed before with enzymes like eptA, [4] mcr-1 is the first polymyxin resistance gene known to be capable of horizontal transfer between different strains of a bacterial species. [1]

mcr-1 also provides resistance to host antimicrobial peptides. Bacteria carrying the gene were better at killing infected caterpillars. [5]

Discovery and geographical spread

The gene was first discovered in E. coli (strain SHP45) from a pig in China April 2011 and published in November 2015. [6] [7] It was identified by independent researchers in human samples from Malaysia, China, [1] England, [8] [9] Scotland, [10] and the United States. [11]

In April 2016, a 49-year-old woman sought medical care at a Pennsylvania clinic for UTI symptoms. PCR of an E. coli isolate cultured from her urine revealed the mcr-1 gene for the first time in the United States, [12] and the CDC sent an alert to health care facilities. In the following twelve months, four additional people were reported to have infections with mcr-1 carrying bacteria. [13]

As of February 2017 mcr-1 has been detected in more than 30 countries on 5 continents in less than a year, [14] and it appears to be spreading in hospitals in China. [15] The prevalence in five Chinese provinces between April 2011 and November 2014 was 15% in raw meat samples and 21% in food animals during 2011–14, and 1% in people hospitalized with infection. [1]

Origins

Using genetic analysis, researchers believe that they have shown that the origins of the gene were on a Chinese pig farm where colistin was routinely used. [16] [17]

Inhibition

Given the importance of mcr-1 in enabling bacteria to acquire polymyxin resistance, MCR-1 (the protein that is encoded by mcr-1) is a current inhibition target for the development of new antibiotics. [18] For example, ethylenediaminetetraacetic acid (EDTA), a metal-chelating agent and common food additive, was shown to inhibit MCR-1 as it is a zinc-dependent enzyme. [3] Substrate analogues, such as ethanolamine and glucose, were also shown to inhibit MCR-1. [19] The use of a combined antibiotics regime has shown to be able to overcome the resistance that is caused by mcr-1, and the mechanism of action may be directly or indirectly targeting the MCR-1 protein. [20]

Other mcr genes

As of April 2021, ten mobilized colistin resistance genes termed mcr-1 through mcr-10 have been identified. They are homologous to each other, and work in similar ways. [21] The mcr-2 gene is a rare variant of mcr-1 and is found only in Belgium. The less-related mcr-3, mcr-4, and mcr-5 were identified in E. coli and Salmonella. [22]

On the phylogenic tree, the various clusters of mcr genes are scattered between immobile resistance genes of the same type, suggesting a history of multiple transfer to plasmids. [23] [24] [19] [25]

See also

Related Research Articles

<span class="mw-page-title-main">Beta-lactamase</span> Class of enzymes

Beta-lactamases (β-lactamases) are enzymes produced by bacteria that provide multi-resistance to beta-lactam antibiotics such as penicillins, cephalosporins, cephamycins, monobactams and carbapenems (ertapenem), although carbapenems are relatively resistant to beta-lactamase. Beta-lactamase provides antibiotic resistance by breaking the antibiotics' structure. These antibiotics all have a common element in their molecular structure: a four-atom ring known as a beta-lactam (β-lactam) ring. Through hydrolysis, the enzyme lactamase breaks the β-lactam ring open, deactivating the molecule's antibacterial properties.

<i>Klebsiella pneumoniae</i> Species of bacterium

Klebsiella pneumoniae is a Gram-negative, non-motile, encapsulated, lactose-fermenting, facultative anaerobic, rod-shaped bacterium. It appears as a mucoid lactose fermenter on MacConkey agar.

<span class="mw-page-title-main">Polymyxin</span> Group of antibiotics

Polymyxins are antibiotics. Polymyxins B and E are used in the treatment of Gram-negative bacterial infections. They work mostly by breaking up the bacterial cell membrane. They are part of a broader class of molecules called nonribosomal peptides.

<span class="mw-page-title-main">Colistin</span> Antibiotic

Colistin, also known as polymyxin E, is an antibiotic medication used as a last-resort treatment for multidrug-resistant Gram-negative infections including pneumonia. These may involve bacteria such as Pseudomonas aeruginosa, Klebsiella pneumoniae, or Acinetobacter. It comes in two forms: colistimethate sodium can be injected into a vein, injected into a muscle, or inhaled, and colistin sulfate is mainly applied to the skin or taken by mouth. Colistimethate sodium is a prodrug; it is produced by the reaction of colistin with formaldehyde and sodium bisulfite, which leads to the addition of a sulfomethyl group to the primary amines of colistin. Colistimethate sodium is less toxic than colistin when administered parenterally. In aqueous solutions it undergoes hydrolysis to form a complex mixture of partially sulfomethylated derivatives, as well as colistin. Resistance to colistin began to appear as of 2015.

Multiple drug resistance (MDR), multidrug resistance or multiresistance is antimicrobial resistance shown by a species of microorganism to at least one antimicrobial drug in three or more antimicrobial categories. Antimicrobial categories are classifications of antimicrobial agents based on their mode of action and specific to target organisms. The MDR types most threatening to public health are MDR bacteria that resist multiple antibiotics; other types include MDR viruses, parasites.

<span class="mw-page-title-main">Efflux pump</span> Protein complexes that move compounds, generally toxic, out of bacterial cells

An efflux pump is an active transporter in cells that moves out unwanted material. Efflux pumps are an important component in bacteria in their ability to remove antibiotics. The efflux could also be the movement of heavy metals, organic pollutants, plant-produced compounds, quorum sensing signals, bacterial metabolites and neurotransmitters. All microorganisms, with a few exceptions, have highly conserved DNA sequences in their genome that encode efflux pumps. Efflux pumps actively move substances out of a microorganism, in a process known as active efflux, which is a vital part of xenobiotic metabolism. This active efflux mechanism is responsible for various types of resistance to bacterial pathogens within bacterial species - the most concerning being antibiotic resistance because microorganisms can have adapted efflux pumps to divert toxins out of the cytoplasm and into extracellular media.

<i>Acinetobacter baumannii</i> Species of bacterium

Acinetobacter baumannii is a typically short, almost round, rod-shaped (coccobacillus) Gram-negative bacterium. It is named after the bacteriologist Paul Baumann. It can be an opportunistic pathogen in humans, affecting people with compromised immune systems, and is becoming increasingly important as a hospital-derived (nosocomial) infection. While other species of the genus Acinetobacter are often found in soil samples, it is almost exclusively isolated from hospital environments. Although occasionally it has been found in environmental soil and water samples, its natural habitat is still not known.

<span class="mw-page-title-main">Fosfomycin</span> Chemical compound

Fosfomycin, sold under the brand name Monurol among others, is an antibiotic primarily used to treat lower urinary tract infections. It is not indicated for kidney infections. Occasionally it is used for prostate infections. It is generally taken by mouth.

An origin of transfer (oriT) is a short sequence ranging from 40-500 base pairs in length that is necessary for the transfer of DNA from a gram-negative bacterial donor to recipient during bacterial conjugation. The transfer of DNA is a critical component for antimicrobial resistance within bacterial cells and the oriT structure and mechanism within plasmid DNA is complementary to its function in bacterial conjugation. The first oriT to be identified and cloned was on the RK2 (IncP) conjugative plasmid, which was done by Guiney and Helinski in 1979.

<span class="mw-page-title-main">Polypeptide antibiotic</span> Class of antibiotics

Polypeptide antibiotics are a chemically diverse class of anti-infective and antitumor antibiotics containing non-protein polypeptide chains. Examples of this class include actinomycin, bacitracin, colistin, and polymyxin B. Actinomycin-D has found use in cancer chemotherapy. Most other polypeptide antibiotics are too toxic for systemic administration, but can safely be administered topically to the skin as an antiseptic for shallow cuts and abrasions.

<span class="mw-page-title-main">New Delhi metallo-beta-lactamase 1</span> Enzyme

NDM-1 is an enzyme that makes bacteria resistant to a broad range of beta-lactam antibiotics. These include the antibiotics of the carbapenem family, which are a mainstay for the treatment of antibiotic-resistant bacterial infections. The gene for NDM-1 is one member of a large gene family that encodes beta-lactamase enzymes called carbapenemases. Bacteria that produce carbapenemases are often referred to in the news media as "superbugs" because infections caused by them are difficult to treat. Such bacteria are usually sensitive only to polymyxins and tigecycline.

<span class="mw-page-title-main">Plasmid-mediated resistance</span> Antibiotic resistance caused by a plasmid

Plasmid-mediated resistance is the transfer of antibiotic resistance genes which are carried on plasmids. Plasmids possess mechanisms that ensure their independent replication as well as those that regulate their replication number and guarantee stable inheritance during cell division. By the conjugation process, they can stimulate lateral transfer between bacteria from various genera and kingdoms. Numerous plasmids contain addiction-inducing systems that are typically based on toxin-antitoxin factors and capable of killing daughter cells that don't inherit the plasmid during cell division. Plasmids often carry multiple antibiotic resistance genes, contributing to the spread of multidrug-resistance (MDR). Antibiotic resistance mediated by MDR plasmids severely limits the treatment options for the infections caused by Gram-negative bacteria, especially family Enterobacteriaceae. The global spread of MDR plasmids has been enhanced by selective pressure from antimicrobial medications used in medical facilities and when raising animals for food.

Carbapenem-resistant Enterobacteriaceae (CRE) or carbapenemase-producing Enterobacteriaceae (CPE) are Gram-negative bacteria that are resistant to the carbapenem class of antibiotics, considered the drugs of last resort for such infections. They are resistant because they produce an enzyme called a carbapenemase that disables the drug molecule. The resistance can vary from moderate to severe. Enterobacteriaceae are common commensals and infectious agents. Experts fear CRE as the new "superbug". The bacteria can kill up to half of patients who get bloodstream infections. Tom Frieden, former head of the Centers for Disease Control and Prevention has referred to CRE as "nightmare bacteria". Examples of enzymes found in certain types of CRE are KPC and NDM. KPC and NDM are enzymes that break down carbapenems and make them ineffective. Both of these enzymes, as well as the enzyme VIM have also been reported in Pseudomonas.

<span class="mw-page-title-main">Antibiotic use in livestock</span> Use of antibiotics for any purpose in the husbandry of livestock

Antibiotic use in livestock is the use of antibiotics for any purpose in the husbandry of livestock, which includes treatment when ill (therapeutic), treatment of a group of animals when at least one is diagnosed with clinical infection (metaphylaxis), and preventative treatment (prophylaxis). Antibiotics are an important tool to treat animal as well as human disease, safeguard animal health and welfare, and support food safety. However, used irresponsibly, this may lead to antibiotic resistance which may impact human, animal and environmental health.

Kluyvera is a Gram negative, facultatively anaerobic bacterial and motile genus from the family of Enterobacteriaceae which have peritrichous flagella. Kluyvera occur in water, soil and sewage. Kluyvera bacteria can cause opportunistic infections in immunocompromised patients.

Escherichia virus CC31, formerly known as Enterobacter virus CC31, is a dsDNA bacteriophage of the subfamily Tevenvirinae responsible for infecting the bacteria family of Enterobacteriaceae. It is one of two discovered viruses of the genus Karamvirus, diverging away from the previously discovered T4virus, as a clonal complex (CC). CC31 was first isolated from Escherichia coli B strain S/6/4 and is primarily associated with Escherichia, even though is named after Enterobacter.

<span class="mw-page-title-main">François Balloux</span> Professor of Computational Biology at UCL

François Balloux is the director of the UCL Genetics Institute, and a professor of computational biology at University College London.

Lipid A phosphoethanolamine transferase is an enzyme that modifies Lipid A by linkage to a phosphoethanolamine moiety. Doing so at some positions reduces the affinity to colistin and related polymyxins, resulting in reduced activity of the antimicrobial. This type of resistance is known as target modification. This type of enzyme is of special medical note, as it offers resistance to a last-resort antibiotic. The modifications also provide cross-resistance to host immunity factors, specifically antimicrobial peptides and lysozyme. EC 2.7.8.43 catalyzes one of the following three reactions:

Timothy Rutland Walsh is a professor working at the University of Oxford. He is a specialist in antimicrobial resistance. Walsh is the Oxford Institute of Antimicrobial Research (IOI) Director of Biology. His work at IOI involves developing new antibiotics to use in animals, to replace use of human antibiotics. His IOI work also involves screening many chemicals to find new antimicrobials that overcome or impede antimicrobial resistance. Also he is involved in documenting the large scale effects of antibiotic resistance in low to middle income countries, such as China, Pakistan Bangladesh, Brazil and several African countries.

References

  1. 1 2 3 4 Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J (February 2016). "Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study". The Lancet. Infectious Diseases. 16 (2): 161–8. doi:10.1016/S1473-3099(15)00424-7. PMID   26603172.
  2. ↑ Reardon S (21 December 2015). "Spread of antibiotic-resistance gene does not spell bacterial apocalypse — yet". Nature. doi:10.1038/nature.2015.19037. S2CID   182042290.
  3. 1 2 Hinchliffe P, Yang QE, Portal E, Young T, Li H, Tooke CL, Carvalho MJ, Paterson NG, Brem J, Niumsup PR, Tansawai U, Lei L, Li M, Shen Z, Wang Y, Schofield CJ, Mulholland AJ, Shen J, Fey N, Walsh TR, Spencer J (January 2017). "Insights into the Mechanistic Basis of Plasmid-Mediated Colistin Resistance from Crystal Structures of the Catalytic Domain of MCR-1". Scientific Reports. 7: 39392. Bibcode:2017NatSR...739392H. doi:10.1038/srep39392. PMC   5216409 . PMID   28059088.
  4. ↑ Anandan A, Evans GL, Condic-Jurkic K, O'Mara ML, John CM, Phillips NJ, Jarvis GA, Wills SS, Stubbs KA, Moraes I, Kahler CM, Vrielink A (February 2017). "Structure of a lipid A phosphoethanolamine transferase suggests how conformational changes govern substrate binding". Proceedings of the National Academy of Sciences of the United States of America. 114 (9): 2218–2223. Bibcode:2017PNAS..114.2218A. doi: 10.1073/pnas.1612927114 . PMC   5338521 . PMID   28193899.
  5. ↑ Jangir PK, Ogunlana L, Szili P, Czikkely M, Shaw LP, Stevens EJ, Yang Y, Yang Q, Wang Y, Pál C, Walsh TR, MacLean CR (25 April 2023). "The evolution of colistin resistance increases bacterial resistance to host antimicrobial peptides and virulence". eLife. 12: e84395. doi: 10.7554/eLife.84395 . PMC   10129329 . PMID   37094804.
  6. ↑ "Newly Reported Gene, mcr-1, Threatens Last-Resort Antibiotics". Antibiotic/Antimicrobial Resistance: AR Solutions in Action. Centers for Disease Control and Prevention. 30 November 2016.
  7. ↑ Gao R, Hu Y, Li Z, Sun J, Wang Q, Lin J, Ye H, Liu F, Srinivas S, Li D, Zhu B, Liu YH, Tian GB, Feng Y (November 2016). "Dissemination and Mechanism for the MCR-1 Colistin Resistance". PLOS Pathogens. 12 (11): e1005957. doi: 10.1371/journal.ppat.1005957 . PMC   5125707 . PMID   27893854.
  8. ↑ Schnirring L (18 December 2015). "More MCR-1 findings lead to calls to ban ag use of colistin". CIDRAP News. CIDRAP — Center for Infectious Disease Research and Policy. Retrieved 2015-12-22.
  9. ↑ McKenna M (3 December 2015). "Apocalypse Pig Redux: Last-Resort Resistance in Europe". Phenomena. Archived from the original on December 8, 2015. Retrieved 28 May 2016.
  10. ↑ "Antibiotic-resistant bacteria detected in Scotland". BBC News. 2016-08-03. Retrieved 2017-03-29.
  11. ↑ The U.S. Military HIV Research Program (MHRP). "First discovery in United States of colistin resistance in a human E. coli infection". ScienceDaily. Retrieved 2016-05-27.
  12. ↑ Wappes J (26 May 2016). "Highly resistant MCR-1 'superbug' found in US for first time". CIDRAP News. CIDRAP — Center for Infectious Disease Research and Policy. Retrieved 2016-08-09.
  13. ↑ "Tracking mcr-1". Antibiotic/Antimicrobial Resistance: Biggest Threats. Centers for Disease Control and Prevention. 24 February 2017. Archived from the original on 17 January 2017. Retrieved 10 January 2017.
  14. ↑ Yi L, Wang J, Gao Y, Liu Y, Doi Y, Wu R, Zeng Z, Liang Z, Liu JH (February 2017). "mcr-1-Harboring Salmonella enterica Serovar Typhimurium Sequence Type 34 in Pigs, China". Emerging Infectious Diseases. 23 (2): 291–295. doi:10.3201/eid2302.161543. PMC   5324782 . PMID   28098547.
  15. ↑ Dall C (27 January 2017). "Studies show spread of MCR-1 gene in China". CIDRAP News. CIDRAP — Center for Infectious Disease Research and Policy.
  16. ↑ Nield D. "A Dangerous Antibiotic-Resistant Gene Has Spread The World. We Now Know Where It Started". ScienceAlert. Retrieved 2018-04-02.
  17. ↑ Wang R, van Dorp L, Shaw LP, Bradley P, Wang Q, Wang X, Jin L, Zhang Q, Liu Y, Rieux A, Dorai-Schneiders T, Weinert LA, Iqbal Z, Didelot X, Wang H, Balloux F (March 2018). "The global distribution and spread of the mobilized colistin resistance gene mcr-1". Nature Communications. 9 (1): 1179. Bibcode:2018NatCo...9.1179W. doi:10.1038/s41467-018-03205-z. PMC   5862964 . PMID   29563494.
  18. ↑ Son SJ, Huang R, Squire CJ, Leung IK (January 2019). "MCR-1: a promising target for structure-based design of inhibitors to tackle polymyxin resistance". Drug Discovery Today. 24 (1): 206–216. doi: 10.1016/j.drudis.2018.07.004 . PMID   30036574.
  19. 1 2 Wei P, Song G, Shi M, Zhou Y, Liu Y, Lei J, Chen P, Yin L (February 2018). "Substrate analog interaction with MCR-1 offers insight into the rising threat of the plasmid-mediated transferable colistin resistance". FASEB Journal. 32 (2): 1085–1098. doi: 10.1096/fj.201700705R . PMID   29079699.
  20. ↑ Zhang Q, Wang RW, Wang MJ, Liu CJ, Moghadam, Wang HB, Ho PL, Li HY, Sun HZ (March 2022). "Re-sensitization of mcr carrying multidrug resistant bacteria to colistin by silver". Proc Natl Acad Sci U S A. 119 (11): e2119417119. Bibcode:2022PNAS..11919417Z. doi: 10.1073/pnas.2119417119 . PMC   8931383 . PMID   35263219.
  21. ↑ Hussein NH, AL-Kadmy IM, Taha BM, et al. (April 2021). "Mobilized colistin resistance (mcr) genes from 1 to 10: a comprehensive review". Mol Biol Rep. 48 (3): 2897–2907. doi:10.1007/s11033-021-06307-y. PMID   33839987. S2CID   233214659.
  22. ↑ Sun J, Zhang H, Liu YH, Feng Y (September 2018). "Towards Understanding MCR-like Colistin Resistance". Trends in Microbiology. 26 (9): 794–808. doi:10.1016/j.tim.2018.02.006. PMID   29525421. S2CID   3865269.
  23. ↑ Carroll LM, Gaballa A, Guldimann C, Sullivan G, Henderson LO, Wiedmann M (May 2019). "Identification of Novel Mobilized Colistin Resistance Gene mcr-9 in a Multidrug-Resistant, Colistin-Susceptible Salmonella enterica Serotype Typhimurium Isolate". mBio. 10 (3): e00853–19. doi:10.1128/mBio.00853-19. PMC   6509194 . PMID   31064835.
  24. ↑ Xu Y, Wei W, Lei S, Lin J, Srinivas S, Feng Y (April 2018). "An Evolutionarily Conserved Mechanism for Intrinsic and Transferable Polymyxin Resistance". mBio. 9 (2). doi:10.1128/mBio.02317-17. PMC   5893884 . PMID   29636432.
  25. ↑ Cuadrat RR, Sorokina M, Andrade BG, Goris T, Dávila AM (2020-05-01). "Global ocean resistome revealed: Exploring antibiotic resistance gene abundance and distribution in TARA Oceans samples". GigaScience. 9 (5). doi:10.1093/gigascience/giaa046. ISSN   2047-217X. PMC   7213576 . PMID   32391909.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.